A team of British researchers, led by Dr. Hugh Brady of Imperial College London’s Department of Life Sciences and publishing in the journal Nature Immunology in mid-September, have identified the master gene that causes blood stem cells to turn into disease-fighting natural killer immune cells. This is a discovery that the team, which included researchers from University College London and the Medical Research Council’s National Institute for Medical Research, believes could one day help scientists boost the body’s production of these frontline tumor-killing cells, creating new ways to treat cancer.
Thermo Fisher Scientific has expanded its line of biotin-binding microplates with the introduction of the Thermo Scientific Pierce High Sensitivity Streptavidin and NeutrAvidin Coated Plates.
The Jackson Laboratory has introduced two new research tools—JAX Mouse Embryonic Stem Cells (mES) and JAX Mouse Embryonic Fibroblasts (MEFs). JAX mES cells are self-renewing, non-transformed cell lines established from day 3.5 blastocysts and can differentiate into all three embryonic germ layers: endoderm, ectoderm and mesoderm.
In a move aimed at the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics, Alnylam Pharmaceuticals Inc. and Tekmira Pharmaceuticals Corp. have joined forces and launched a new company, AlCana Technologies Inc.
Avila Therapeutics Inc. has entered into an option agreement with the Novartis Option Fund focused on Avila’s advancement of a novel covalent drug program from Avila’s research pipeline in conjunction with an equity investment
BioFocus DPI and Oncodesign have pooled their expertise and resources to form a drug discovery service specializing in the rapid generation of promising anticancer drugs
Upgrading sample management and storage can represent a significant initial investment, but the benefits far exceed the costs. By upgrading sample management systems, the “elephant in the room” can be exposed and removed, saving time and money and averting a wide range of problems.
Or is it? This is the title I used at an American Chemical Society symposium on clinical chemistry in the late 1970s. Even in my youth, I was complaining about analytical chemistry faculty doing things that had very little biological relevance, when it was not that hard to do the opposite. Thirty years later, I’ve had to modify my opinion because urine, blood, rats, tissue, saliva and all the rest have recently become very expensive, and properly so.
On Aug. 25, Massachusetts Sen. Edward “Ted” Kennedy passed away at the age of 77 after battling a malignant glioma, leaving our nation to celebrate his accomplishments and wonder how his passing will affect Congress’ current healthcare reform proposals.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.